Tango Therapeutics (TNGX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TNGX Tango Therapeutics

Watchlist

9.160
-1.730-15.89%

Close Sep 9 16:00 ET

9.250
+0.090+0.98%

Post 19:46 ET

981.44MMarket Cap-8252P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Small U.S. Stocks Finish Mixed As Xencor Lead, Tango Therapeutics Lags
Dow Jones16:20 ET
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsSep 9 07:31 ET · Ratings
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsSep 9 04:32 ET · Ratings
Barclays Issues a Buy Rating on Tango Therapeutics (TNGX)
TipRanksSep 9 03:55 ET · Ratings
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Shares Climb 29% But Its Business Is Yet to Catch Up
Simply Wall StSep 1 08:03 ET
Tango Therapeutics to Participate in Upcoming Investor Conferences
newsfilter.ioAug 28 07:00 ET

Comments

Jaguar8

May 23 07:05

$Tango Therapeutics (TNGX.US)$
NEWS
Tango Therapeutics Announces Discontinuation of TNG348 Program

Moomoo AI

Mar 21 06:10

Analysts opine that ongoing losses overshadow higher revenue estimates for Tango Therapeutics. The narrow estimate spread indicates easy valuation or heavy reliance on key assumptions. The company's revenues are predicted to lag behind the industry.

Earnings Update: Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported And Analysts Are Boosting Their Estimates

Moomoo AI

Dec 13, 2023 04:27

Tango Therapeutics' strong share price surge has led to a soaring P/S, but forecasted future revenues may not support this high P/S ratio. With below-industry-average revenue growth predicted, caution is advised as this could potentially harm long-term share prices.

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%

Moomoo AI

Nov 9, 2023 08:04

While slowing growth is anticipated for Tango Therapeutics compared to the wider market, its analysts are optimistic about substantial improvements in the sales pipeline.